Literature DB >> 12485996

Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains.

Donna L Mallery1, Cassandra J Vandenberg, Kevin Hiom.   

Abstract

Loss of the tumour suppressor BRCA1 results in profound chromosomal instability. The fundamental defect underlying this catastrophic phenotype is not yet known. In vivo, BRCA1 forms a heterodimeric complex with BARD1. Both proteins contain an N-terminal zinc RING-finger domain which confers E3 ubiquitin ligase activity. We have isolated full-length human BRCA1/BARD1 complex and have shown that it has a dual E3 ubiquitin ligase activity. First, it mediates the monoubiquitylation of nucleosome core histones in vitro, including the variant histone H2AX that co-localizes with BRCA1 at sites of DNA damage. Secondly, BRCA1/BARD1 catalyses the formation of multiple polyubiquitin chains on itself. Remarkably, this auto-polyubiquitylation potentiates the E3 ubiquitin ligase activity of the BRCA1/BARD1 complex >20-fold. Even though BRCA1 has been reported to associate with a C-terminal ubiquitin hydrolase, BAP1, this enzyme does not appear to function in the deubiquitylation of the BRCA1/BARD1 complex.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12485996      PMCID: PMC139111          DOI: 10.1093/emboj/cdf691

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  33 in total

Review 1.  Roles of BRCA1 and its interacting proteins.

Authors:  C X Deng; S G Brodie
Journal:  Bioessays       Date:  2000-08       Impact factor: 4.345

2.  BRCA1 physically associates with p53 and stimulates its transcriptional activity.

Authors:  H Zhang; K Somasundaram; Y Peng; H Tian; H Zhang; D Bi; B L Weber; W S El-Deiry
Journal:  Oncogene       Date:  1998-04-02       Impact factor: 9.867

Review 3.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

4.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.

Authors:  D E Jensen; M Proctor; S T Marquis; H P Gardner; S I Ha; L A Chodosh; A M Ishov; N Tommerup; H Vissing; Y Sekido; J Minna; A Borodovsky; D C Schultz; K D Wilkinson; G G Maul; N Barlev; S L Berger; G C Prendergast; F J Rauscher
Journal:  Oncogene       Date:  1998-03-05       Impact factor: 9.867

5.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product.

Authors:  L C Wu; Z W Wang; J T Tsan; M A Spillman; A Phung; X L Xu; M C Yang; L Y Hwang; A M Bowcock; R Baer
Journal:  Nat Genet       Date:  1996-12       Impact factor: 38.330

6.  BRCA1 is a component of the RNA polymerase II holoenzyme.

Authors:  R Scully; S F Anderson; D M Chao; W Wei; L Ye; R A Young; D M Livingston; J D Parvin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

7.  Rad6-dependent ubiquitination of histone H2B in yeast.

Authors:  K Robzyk; J Recht; M A Osley
Journal:  Science       Date:  2000-01-21       Impact factor: 47.728

8.  Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes.

Authors:  L C Dang; F D Melandri; R L Stein
Journal:  Biochemistry       Date:  1998-02-17       Impact factor: 3.162

9.  A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage.

Authors:  T T Paull; E P Rogakou; V Yamazaki; C U Kirchgessner; M Gellert; W M Bonner
Journal:  Curr Biol       Date:  2000 Jul 27-Aug 10       Impact factor: 10.834

10.  Association of BRCA1 with Rad51 in mitotic and meiotic cells.

Authors:  R Scully; J Chen; A Plug; Y Xiao; D Weaver; J Feunteun; T Ashley; D M Livingston
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

View more
  109 in total

1.  The RAG1 N-terminal domain is an E3 ubiquitin ligase.

Authors:  Vyacheslav Yurchenko; Zhu Xue; Moshe Sadofsky
Journal:  Genes Dev       Date:  2003-03-01       Impact factor: 11.361

2.  Degradation of transcription repressor ZBRK1 through the ubiquitin-proteasome pathway relieves repression of Gadd45a upon DNA damage.

Authors:  Jeanho Yun; Wen-Hwa Lee
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

3.  BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number.

Authors:  Lea M Starita; Yuka Machida; Satish Sankaran; Joshua E Elias; Karen Griffin; Brian P Schlegel; Steven P Gygi; Jeffrey D Parvin
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

4.  The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function.

Authors:  Foon Wu-Baer; Thomas Ludwig; Richard Baer
Journal:  Mol Cell Biol       Date:  2010-03-29       Impact factor: 4.272

5.  Quantitative proteomic identification of the BRCA1 ubiquitination substrates.

Authors:  Meihua Song; Kevin Hakala; Susan T Weintraub; Yuzuru Shiio
Journal:  J Proteome Res       Date:  2011-10-11       Impact factor: 4.466

Review 6.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

7.  Characterization of E3Histone, a novel testis ubiquitin protein ligase which ubiquitinates histones.

Authors:  Zhiqian Liu; Rose Oughtred; Simon S Wing
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

Review 8.  The Role of Additional Sex Combs-Like Proteins in Cancer.

Authors:  Jean-Baptiste Micol; Omar Abdel-Wahab
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

9.  Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.

Authors:  M K Sauer; I L Andrulis
Journal:  J Med Genet       Date:  2005-08       Impact factor: 6.318

Review 10.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.